Revolutionary Breakthrough: New Drug Prototype Regenerates Lung Tissue
In an extraordinary leap forward for medical science, a group of scientists at Scripps Research and its drug discovery arm, the Calibr-Skaggs Institute for Innovative Medicines, have developed a new drug prototype that has the potential to regenerate damaged lung tissue. This innovative treatment could be a game-changer for patients suffering from respiratory diseases. The […]
Revolutionary Breakthrough in Pulmonary Fibrosis Treatment
Surrozen Inc. has recently published a study in “Respiratory Research” that showcases the potential of its Wnt mimetic antibody to effectively treat pulmonary fibrosis. Utilizing an acute bleomycin model, this preclinical research demonstrates the antibody’s ability to decrease inflammation and fibrosis while improving lung function. Understanding Pulmonary Fibrosis and Wnt Pathway’s Role Pulmonary fibrosis is […]
Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)
LIBERTY, Mo., May 2, 2022 /PRNewswire/ — Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) to move forward with Phase II Outpatient Clinical Trial using a combination of Umbilical Cord […]